Skip to main content
Equibles
ZBH logo

ZBH · Zimmer Biomet Holdings, Inc. · Metrics

Track ZBH — free

Use ZBH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZBH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$103.21 -1.35 (-1.29%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
S&P 500 member Russell 1000 member Rebalance outlook locked
Customer concentration — top customer 12% of receivables

One customer — 12% of receivables (As of September 30, 2026)

“As of September 30, 2026, one customer represented approximately 12% of our consolidated accounts receivable.”
View the 10-Q filed Nov 4, 2026
Market Cap
$19.53B
Shares
189.25M
Volume · Nov 13 2.52M Avg daily vol (3M) 2.05M

ZBH metrics

117 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$103.21
Market cap
$19.53B

Price action

23 metrics
Price change (1W)
-2.3%
Price change (30D)
+9.4%
Price change (3M)
+2.5%
Price change (6M)
+23.3%
Price change (YTD)
+14.8%
Price change (1Y)
+14.0%
Trailing year
Price change (5Y)
—
52-week high
$110.15
52-week low
$79.58
Change from 52-week high
-6.3%
Change from 52-week low
+29.7%
Annualized volatility
32.4%
Annualized volatility (3M)
39.3%
Implied volatility (30D)
28.5%
IV rank (1Y)
26.7
IV percentile (1Y)
39.5
Beta
0.4
RSI (14D)
55.9
Price vs SMA 50
+7.8%
Price vs SMA 200
+11.5%
Avg volume (3M)
2.05M
Relative volume
1.2
Average dollar volume
$198.98M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
189.25M

Valuation

12 metrics
P / E (TTM)
26.1
Trailing earnings · reciprocal yield 3.8%
PEG ratio
—
EV / revenue
3.1×
reciprocal yield 32.2%
EV / EBITDA
11.7×
reciprocal yield 8.5%
EV / EBIT
22.9×
reciprocal yield 4.4%
P / sales
2.3×
reciprocal yield 43.9%
P / book
1.5
reciprocal yield 65.1%
FCF yield
8.4%
TTM · current market cap
Buyback yield
4.2%
P / FCF
11.9
reciprocal yield 8.4%
P / operating cash flow
10.4
reciprocal yield 9.6%
Earnings yield
3.9%

Historical valuation

8 metrics
P / E historical average (3Y)
25.6×
reciprocal yield 3.9%
P / E historical average (5Y)
37.1×
reciprocal yield 2.7%
EV / revenue historical average (3Y)
3.4×
reciprocal yield 29.2%
EV / revenue historical average (5Y)
3.7×
reciprocal yield 26.8%
EV / EBIT historical average (3Y)
22.4×
reciprocal yield 4.5%
EV / EBIT historical average (5Y)
29.2×
reciprocal yield 3.4%
EV / EBITDA historical average (3Y)
12.1×
reciprocal yield 8.3%
EV / EBITDA historical average (5Y)
14.2×
reciprocal yield 7.0%

Dividends & buybacks

7 metrics
Dividend yield
0.9%
Trailing 12 months
Payout ratio
24.3%
Shareholder yield
5.2%
Dividend / share (TTM)
$0.96
Dividend growth YoY
+0.0%
Dividend growth streak
0
Last ex-dividend
2026-09-30

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-04

Profitability

9 metrics
Gross margin
69.7%
Operating margin
13.6%
Trailing 12 months
Net margin
9.0%
Gross profit (TTM)
$5.97B
Operating profit (TTM)
$1.16B
Net income (TTM)
$767.40M
Trailing 12 months
Diluted EPS (TTM)
$3.96
FCF margin
19.2%
Effective tax rate
13.1%

Per share

11 metrics
Revenue per diluted share (TTM)
$44.06
Gross profit per diluted share (TTM)
$30.71
Operating profit per diluted share (TTM)
$5.98
EBITDA per diluted share (TTM)
$11.68
Net income per diluted share (TTM)
$3.95
Operating cash flow per diluted share (TTM)
$9.70
Free cash flow per diluted share (TTM)
$8.46
Capital expenditures per diluted share (TTM)
$1.24
R&D per diluted share (TTM)
$2.22
Stock compensation per diluted share (TTM)
$0.50
Book value per share
$27.09

Growth

11 metrics
Revenue growth YoY
+3.1%
Year over year
Net income growth YoY
-17.0%
Revenue (TTM)
$8.57B
Trailing 12 months
EPS growth YoY
-13.8%
Shares change YoY
-3.7%
Year over year · fewer shares
Revenue CAGR (3Y)
+5.9%
Revenue CAGR (5Y)
+6.1%
EPS CAGR (3Y)
+47.8%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+8.0%
FCF CAGR (5Y)
+6.2%

Quality

14 metrics
Return on equity
6.0%
Return on assets
3.3%
Debt / equity
0.6
Current ratio
1.5
EBITDA (TTM)
$2.27B
Free cash flow (TTM)
$1.64B
Quick ratio
0.8
Interest coverage
—
Net debt / EBITDA
3.1
Return on invested capital
5.1%
Trailing 12 months
Net cash
−$7.10B
Latest balance sheet
Cash & equivalents
$399.90M
Total assets
$23.54B
Total debt
$7.50B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.88B
Capital expenditures (TTM)
$241.10M
R&D (TTM)
$432.80M
SG&A (TTM)
$3.48B
Stock compensation (TTM)
$97.10M
R&D / revenue
5.0%
Stock compensation / revenue
1.1%

Ownership (13F)

9 metrics
13F filers
918
13F filer change QoQ
-5
Institutional ownership
105.4%
Conviction holders (share of 13F filers)
0.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.9%
Holder tenure
15.4
Price vs estimated holder cost
-9.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
24.0%

Short interest

3 metrics
Short interest
4.1%
Latest settlement · 3.9 days to cover
Days to cover
3.9d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$824,028
Insider-sentiment score
34 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1136869 CUSIP 98956P102 13F (30d) 793 filings 700 filers Visit website Investor relations